Sangamo Therapeutics News

Sangamo Therapeutics Analyst Ratings

BenzingaMar 19 06:24 ET

Sangamo Therapeutics Analyst Ratings

BenzingaMar 14 11:26 ET

Sangamo Therapeutics Analyst Ratings

BenzingaMar 13 12:47 ET

Sangamo Therapeutics Analyst Ratings

BenzingaFeb 12 12:46 ET

Sangamo Therapeutics Analyst Ratings

BenzingaFeb 6 08:46 ET

Sangamo Therapeutics Analyst Ratings

BenzingaJan 19 06:57 ET

Wells Fargo Downgrades Sangamo, Cites Removal of Key Year-end Catalyst

Seeking AlphaNov 6, 2023 14:45 ET

Wells Fargo Downgrades Sangamo Therapeutics to Equal-Weight, Announces $1 Price Target

BenzingaNov 6, 2023 08:21 ET

Sangamo Therapeutics Analyst Ratings

BenzingaNov 6, 2023 08:19 ET

RBC Capital Downgrades Sangamo Therapeutics to Sector Perform, Lowers Price Target to $2

BenzingaNov 3, 2023 06:20 ET

Sangamo Therapeutics Analyst Ratings

BenzingaNov 3, 2023 06:19 ET

Truist Securities Maintains Buy on Sangamo Therapeutics, Lowers Price Target to $7

BenzingaAug 15, 2023 10:37 ET

Sangamo Therapeutics Analyst Ratings

BenzingaAug 15, 2023 10:36 ET

H.C. Wainwright Reaffirms Their Buy Rating on Sangamo Biosciences (SGMO)

TipRanksAug 14, 2023 08:36 ET

Sangamo Therapeutics Analyst Ratings

BenzingaAug 14, 2023 06:16 ET

Sangamo Therapeutics Analyst Ratings

BenzingaAug 11, 2023 10:37 ET

Wedbush Lowers Sangamo Therapeutics' Price Target to $10 From $16, Keeps Outperform Rating

MT NewswiresAug 11, 2023 07:08 ET

Wells Fargo Maintains Overweight on Sangamo Therapeutics, Lowers Price Target to $4

BenzingaAug 10, 2023 10:08 ET

Sangamo Therapeutics Analyst Ratings

BenzingaAug 10, 2023 10:06 ET

Barclays Maintains Overweight on Sangamo Therapeutics, Lowers Price Target to $9

BenzingaAug 9, 2023 12:15 ET